February 15, 2013 writer


Québec City, February 15, 2013 – TSO3 Inc. (“TSO3”) (TSX: TOS) an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has filed a preliminary short form prospectus with the securities regulatory authorities in all provinces of Canada with respect to a previously announced public offering of 7,000,000 common shares (the “Common Shares”) at the price of CDN $1.00 per Common Share (the “Issue Price”) for aggregate gross proceeds to TSO3 of CDN $7,000,000 (“the Offering”).

The offering is being made on a bought deal basis through a syndicate of underwriters co-led by Desjardins Capital Markets and Canaccord Genuity Corp. and including Byron Capital Ltd. and Laurentian Bank Securities Inc. (collectively, the “Underwriters”). The Offering is expected to close on or about March 4, 2013 and is subject to customary conditions and regulatory approvals.

As the Company actively pursues US regulatory clearance for the STERIZONE® 125L+ Sterilizer, net proceeds from the Offering will be used to strengthen the Company’s financial position in negotiating a channel partner agreement. The proceeds will also allow for continued new product development.

This news release is not an offer of securities for sale in the United States and is not an offer to sell or solicitation of an offer to buy any securities of the Company, nor shall it form the basis of, or be relied upon in connection with any contract for purchase or subscription. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933 (the “Securities Act”) or an exemption from registration thereunder. These securities have not been and will not be registered under the Securities Act or the securities laws of any state and may not be offered or sold in the United States absent registration under the Securities Act and applicable state securities laws or pursuant to an applicable exemption therefrom.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential.  TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.

For more information about TSO3, visit the Company’s Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.



Back to Posts